{"DataElement":{"publicId":"8178009","version":"1","preferredName":"Anti-Thymocyte Globulin Administered End Date","preferredDefinition":"The date the administered Anti-Thymocyte Globulin ended.","longName":"ATG_END_DATE","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"4182056","version":"1","preferredName":"Anti-Thymocyte Globulin Administered","preferredDefinition":"A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease._The act of having given something (e.g., a medication or test).","longName":"4182054v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"4182054","version":"1","preferredName":"Anti-Thymocyte Globulin","preferredDefinition":"A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","longName":"C278","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36A2E6C-D8A3-314A-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-27","modifiedBy":"ONEDATA","dateModified":"2014-02-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36A2E6C-D8B1-314A-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-02-27","modifiedBy":"NYCHM","dateModified":"2017-03-01","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6430489","version":"1","preferredName":"End Date","preferredDefinition":"The calendar date on which something is to terminate or did terminate.","longName":"6430489v1.0","context":"COG","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2178073","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"EDRN","contextVersion":"1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"CC049DE1-E96E-5FB4-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6430488","version":"1","preferredName":"End Date","preferredDefinition":"The calendar date on which something is to terminate or did terminate.","longName":"C68617","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End Date","conceptCode":"C68617","definition":"The calendar date on which something is to terminate or did terminate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76168B6F-130E-72CD-E053-F662850A44E6","latestVersionIndicator":"Yes","beginDate":"2018-09-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-17","modifiedBy":"ONEDATA","dateModified":"2018-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76168B6F-131F-72CD-E053-F662850A44E6","latestVersionIndicator":"Yes","beginDate":"2018-09-17","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-17","modifiedBy":"LEEW","dateModified":"2018-11-05","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the date the adminis","type":"Preferred Question Text","description":"What was the date the administered Anti-Thymocyte Globulin ended?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"End date of ATG administration during this reporting period:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDB88416-EC6C-2390-E053-4EBD850A13A4","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-28","modifiedBy":"KUMMEROA","dateModified":"2022-08-25","changeDescription":null,"administrativeNotes":"2022.8.25 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}